Columbia University, Irving Medical Center
Columbia University, Irving Medical Center
New York, New York, United States3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Enrolling by invitation | Phase 1 / Phase 2 | 2026-08-03 | NCT07743268 | |
| Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Enrolling by invitation | Phase 1 / Phase 2 | 2026-07-13 | NCT07095686 | |
| Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT06977451 |